CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Retrospective Analysis on the Efficacy, Safety and Treatment Failure Group of Sitagliptin for Mean 10-Month Duration
Won Jun Kim, Cheol-Young Park, Eun Haeng Jeong, Jeong Youn Seo, Ji Soo Seol, Se Eun Park, Eun Jung Rhee, Won Young Lee, Ki Won Oh, Sung Woo Park, Sun Woo Kim
Diabetes Metab J. 2011;35(3):290-297.   Published online June 30, 2011
DOI: https://doi.org/10.4093/dmj.2011.35.3.290

Excel Download

Retrospective Analysis on the Efficacy, Safety and Treatment Failure Group of Sitagliptin for Mean 10-Month Duration
Diabetes & Metabolism Journal. 2011;35(3):290   Crossref logo
Link1 Link2 Link3

Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes*
Diabetes, Obesity and Metabolism. 2008;10(10):959-969   Crossref logo
Link1 Link2

Efficacy and Safety of Sitagliptin Therapy Compared with Pioglitazone in Heart Failure Patients with Type 2 Diabetes
Journal of Cardiac Failure. 2012;18(10):S188   Crossref logo
Link1 Link2

DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide
Diabetic Medicine. 2011;28(6):705-714   Crossref logo
Link1 Link2

Efficacy and Safety of Sitagliptin in the Treatment of Type 2 Diabetes
Clinical Medicine. Therapeutics. 2009;1:CMT.S2313   Crossref logo
Link1 Link2 Link3

Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)
Diabetes Care. 2012;35(2):252-258   Crossref logo
Link1 Link2

A Retrospective Analysis of the Efficacy and Safety of Anlotinib in the Treatment of Advanced Sarcoma
. 2021;   Crossref logo
Link1 Link2

Long-Term Efficacy and Safety of Treatments for Osteoporosis
The Duration and Safety of Osteoporosis Treatment. 2016;203-232   Crossref logo
Link1

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus
Diabetologia. 2006;49(11):2564-2571   Crossref logo
Link1 Link2 Link3

Retrospective analysis of the efficacy and safety of adalimumab 40 mg e.o.w. in patients with moderate to severe plaque psoriasis in a range of treatment duration from 4 to 52 months
Journal of the American Academy of Dermatology. 2014;70(5):AB183   Crossref logo
Link1 Link2